Review article · 2017 · Open access

Drug candidates in clinical trials for Alzheimer’s disease

Shih‐Ya Hung, Wen Fu

Journal of Biomedical Science, 24(1), 47 · Published 19 July 2017 · DOI 10.1186/s12929-017-0355-7

Open full textCite this paper

In brief

“Drug candidates in clinical trials for Alzheimer’s disease” is a 2017 review article by Shih‐Ya Hung and Wen Fu, published in Journal of Biomedical Science. OpenAlex counts 461 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at Journal of Biomedical Science.

Citations
461
Most cited in
2018 (75)
Field-weighted impact
5.75
References
73
Authors
2

Abstract

Alzheimer’s disease (AD) is a major form of senile dementia, characterized by progressive memory and neuronal loss combined with cognitive impairment. AD is the most common neurodegenerative disease worldwide, affecting one-fifth of those aged over 85 years. Recent therapeutic approaches have been strongly influenced by five neuropathological hallmarks of AD: acetylcholine deficiency, glutamate excitotoxicity, extracellular deposition of amyloid-β (Aβ plague), formation of intraneuronal neurofibrillary tangles (NTFs), and neuroinflammation. The lowered concentrations of acetylcholine (ACh) in AD result in a progressive and significant loss of cognitive and behavioral function. Current AD medications, memantine and acetylcholinesterase inhibitors (AChEIs) alleviate some of these symptoms by enhancing cholinergic signaling, but they are not curative. Since 2003, no new drugs have been approved for the treatment of AD. This article focuses on the current research in clinical trials targeting the neuropathological findings of AD including acetylcholine response, glutamate transmission, Aβ clearance, tau protein deposits, and neuroinflammation. These investigations include acetylcholinesterase inhibitors, agonists and antagonists of neurotransmitter receptors, β-secretase (BACE) or γ-secretase inhibitors, vaccines or antibodies targeting Aβ clearance or tau protein, as well as anti-inflammation compounds. Ongoing Phase III clinical trials via passive immunotherapy against Aβ peptides (crenezumab, gantenerumab, and aducanumab) seem to be promising. Using small molecules blocking 5-HT 6 serotonin receptor (intepirdine), inhibiting BACE activity (E2609, AZD3293, and verubecestat), or reducing tau aggregation (TRx0237) are also currently in Phase III clinical trials. We here systemically review the findings from recent clinical trials to provide a comprehensive review of novel therapeutic compounds in the treatment and prevention of AD.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Hung, S., & Fu, W. (2017). Drug candidates in clinical trials for Alzheimer’s disease. Journal of Biomedical Science, 24(1), 47. https://doi.org/10.1186/s12929-017-0355-7

MLA 9

Hung, Shih‐Ya, and Wen Fu. “Drug candidates in clinical trials for Alzheimer’s disease.” Journal of Biomedical Science, vol. 24, no. 1, 2017, p. 47. https://doi.org/10.1186/s12929-017-0355-7.

Chicago

Hung, Shih‐Ya and Wen Fu. 2017. “Drug candidates in clinical trials for Alzheimer’s disease.” Journal of Biomedical Science 24 (1): 47. https://doi.org/10.1186/s12929-017-0355-7.

Harvard

Hung, S. and Fu, W. (2017) ‘Drug candidates in clinical trials for Alzheimer’s disease’, Journal of Biomedical Science, 24(1), p. 47. doi:10.1186/s12929-017-0355-7.

IEEE

S. Hung and W. Fu, “Drug candidates in clinical trials for Alzheimer’s disease,” Journal of Biomedical Science, vol. 24, no. 1, p. 47, 2017, doi: 10.1186/s12929-017-0355-7.

BibTeX

@article{hung2017drug,
  title     = {{Drug candidates in clinical trials for Alzheimer’s disease}},
  author    = {Hung, Shih‐Ya and Fu, Wen},
  journal   = {Journal of Biomedical Science},
  year      = {2017},
  volume    = {24},
  number    = {1},
  pages     = {47},
  doi       = {10.1186/s12929-017-0355-7},
  url       = {https://doi.org/10.1186/s12929-017-0355-7}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20171212
20187575
20196868
20205959
20215050
20225454
20235252
20244242
20253030
20261717

Its field-weighted citation impact is 5.75: it has been cited 5.75 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • drug candidates
  • clinical trials
  • acetylcholinesterase inhibitors
  • memantine
  • acetylcholine deficiency
  • glutamate excitotoxicity
  • amyloid-beta clearance

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Hung, S., & Fu, W. (2017). Drug candidates in clinical trials for Alzheimer’s disease. Journal of Biomedical Science, 24(1), 47. https://doi.org/10.1186/s12929-017-0355-7

How many times has this paper been cited?

461 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Biomedical Science: sign in and open the full text from this page.

Who wrote this paper?

Shih‐Ya Hung, Wen Fu.

What is the DOI of this paper?

10.1186/s12929-017-0355-7, permanently at https://doi.org/10.1186/s12929-017-0355-7. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.